| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Undurti N Da. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Medical science monitor : international medical journal of experimental and clinical research. vol 13. issue 12. 2008-04-11. PMID:18049445. |
recent studies showed that the plasma and tissue activities of enzymes butyrylcholinesterase and acetylcholinesterase are elevated in patients with alzheimer's disease, and diabetes mellitus, hypertension, insulin resistance, and hyperlipidemia. |
2008-04-11 |
2023-08-12 |
Not clear |
| L Cibicková, V Palicka, N Cibicek, E Cermáková, S Micuda, L Bartosová, D Ju. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiological research. vol 56. issue 6. 2008-04-09. PMID:17087598. |
acetylcholinesterase (ache) inhibitors represent standard treatment of alzheimer's disease. |
2008-04-09 |
2023-08-12 |
rat |
| Toshiaki Sunazuka, Tomoyasu Hirose, Satoshi Omur. Efficient total synthesis of novel bioactive microbial metabolites. Accounts of chemical research. vol 41. issue 2. 2008-04-08. PMID:18217720. |
fo-4259 by our screening of microbial metabolites that strongly inhibit acetylcholinesterase (ache) in order to create novel medicines for alzheimer's disease (ad). |
2008-04-08 |
2023-08-12 |
human |
| Maria Laura Bolognesi, Andrea Cavalli, Luca Valgimigli, Manuela Bartolini, Michela Rosini, Vincenza Andrisano, Maurizio Recanatini, Carlo Melchiorr. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. Journal of medicinal chemistry. vol 50. issue 26. 2008-04-03. PMID:18047264. |
multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against alzheimer's disease. |
2008-04-03 |
2023-08-12 |
human |
| J Baruah, J Easby, G Kessel. Effects of acetylcholinesterase inhibitor therapy for Alzheimer's disease on neuromuscular block. British journal of anaesthesia. vol 100. issue 3. 2008-03-24. PMID:18276655. |
effects of acetylcholinesterase inhibitor therapy for alzheimer's disease on neuromuscular block. |
2008-03-24 |
2023-08-12 |
Not clear |
| AiLin Liu, HongMei Guang, LiYa Zhu, GuanHua Du, Simon M Y Lee, YiTao Wan. 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors. Science in China. Series C, Life sciences. vol 50. issue 6. 2008-03-18. PMID:17914643. |
acetylcholinesterase (ache) inhibitors are an important class of medicinal agents used for the treatment of alzheimer's disease. |
2008-03-18 |
2023-08-12 |
Not clear |
| Geri Brousseau, Byron P Rourke, Brian Burk. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Experimental and clinical psychopharmacology. vol 15. issue 6. 2008-03-17. PMID:18179307. |
acetylcholinesterase inhibitors, neuropsychiatric symptoms, and alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. |
2008-03-17 |
2023-08-12 |
Not clear |
| Amélia P Rauter, Isabel Branco, Rui G Lopes, Jorge Justino, Filipa V M Silva, João P Noronha, Eurico J Cabrita, Ignacio Brouard, Jaime Bermej. A new lupene triterpenetriol and anticholinesterase activity of Salvia sclareoides. Fitoterapia. vol 78. issue 7-8. 2008-03-06. PMID:17570616. |
the acetone, ethanol, butanol and water extracts of the plant were screened for the in vitro inhibitory activity of acetylcholinesterase (ache) and butyrilcholinesterase (bche), enzymes which play a role in the alzheimer disease. |
2008-03-06 |
2023-08-12 |
Not clear |
| Hui Ming Ge, Chun Hua Zhu, Da Hua Shi, Li Dong Zhang, Dai Qian Xie, Jie Yang, Seik Weng Ng, Ren Xiang Ta. Hopeahainol A: an acetylcholinesterase inhibitor from Hopea hainanensis. Chemistry (Weinheim an der Bergstrasse, Germany). vol 14. issue 1. 2008-02-28. PMID:17943703. |
hopeahainol a was an acetylcholinesterase inhibitor with an ic50 value of 4.33 microm, which is comparable to that of huperzine a, a presently prescribed drug for the treatment of alzheimer, while other similar structures were inactive. |
2008-02-28 |
2023-08-12 |
Not clear |
| T Darreh-Shori, A Kadir, O Almkvist, M Grut, A Wall, G Blomquist, B Eriksson, B Långström, A Nordber. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiology of aging. vol 29. issue 2. 2008-02-21. PMID:17196712. |
the relationship between acetylcholinesterase (ache) activity in the csf and brain of patients with alzheimer's disease (ad) was investigated in 18 mild ad patients following galantamine treatment. |
2008-02-21 |
2023-08-12 |
Not clear |
| Liliya Georgieva, Strahil Berkov, Violeta Kondakova, Jaume Bastida, Francesc Viladomat, Atanas Atanassov, Carles Codin. Alkaloid variability in Leucojum aestivum from wild populations. Zeitschrift fur Naturforschung. C, Journal of biosciences. vol 62. issue 9-10. 2008-02-21. PMID:18069233. |
leucojum aestivum (summer snowflake) is a plant species used for the extraction of galanthamine, an acetylcholinesterase inhibitor for the treatment of alzheimer's disease. |
2008-02-21 |
2023-08-12 |
Not clear |
| Luis Marco, Maria do Carmo Carreira. Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent patents on CNS drug discovery. vol 1. issue 1. 2008-02-15. PMID:18221196. |
(-)-galanthamine is a selective, reversible competitive acetylcholinesterase inhibitor that has been recently approved for the symptomatic treatment of alzheimer's disease. |
2008-02-15 |
2023-08-12 |
Not clear |
| Naoko Kaneko, Kazunobu Sawamot. [Neuronal migration in the adult brain]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 27. issue 5-6. 2008-02-14. PMID:18154043. |
we found that long-term administration of donepezil, an acetylcholinesterase inhibitor clinically used for the treatment of alzheimer's disease, promotes the survival of newly-generated neurons in the ob and the dg. |
2008-02-14 |
2023-08-12 |
mouse |
| Ana Alfirevic, Tracy Mills, Daniel Carr, Bryan J Barratt, Ansar Jawaid, James Sherwood, John C Smith, Jonathan Tugwood, Ruben Hartkoorn, Andrew Owen, Kevin B Park, Munir Pirmohame. Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenetics and genomics. vol 17. issue 12. 2008-01-22. PMID:18004213. |
tacrine, the first acetylcholinesterase inhibitor used in the treatment of alzheimer's disease, is associated with transaminase elevation in up to 50% of patients. |
2008-01-22 |
2023-08-12 |
Not clear |
| Allam A Rao, Gumpeny R Sridhar, Undurti N Da. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Medical hypotheses. vol 69. issue 6. 2008-01-03. PMID:17553629. |
elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and alzheimer's disease. |
2008-01-03 |
2023-08-12 |
Not clear |
| Allam A Rao, Gumpeny R Sridhar, Undurti N Da. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Medical hypotheses. vol 69. issue 6. 2008-01-03. PMID:17553629. |
recent studies revealed that plasma and tissue concentrations of enzymes butyrylcholinesterase and acetylcholinesterase are elevated in type 2 diabetes and alzheimer's disease. |
2008-01-03 |
2023-08-12 |
Not clear |
| Allam A Rao, Gumpeny R Sridhar, Undurti N Da. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Medical hypotheses. vol 69. issue 6. 2008-01-03. PMID:17553629. |
hence, elevated butyrylcholinesterase and acetylcholinesterase concentrations will lead to a decrease in the levels of acetylcholine that could trigger the onset of low-grade systemic inflammation seen in type 2 diabetes and alzheimer's disease. |
2008-01-03 |
2023-08-12 |
Not clear |
| Allam A Rao, Gumpeny R Sridhar, Undurti N Da. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Medical hypotheses. vol 69. issue 6. 2008-01-03. PMID:17553629. |
in view of this, we propose that butyrylcholinesterase and acetylcholinesterase will not only serve as therapeutic targets but also may serve as markers to predict the development of type 2 diabetes mellitus and alzheimer's disease. |
2008-01-03 |
2023-08-12 |
Not clear |
| Eun Kyoung Ryu, Xiaoyuan Che. Development of Alzheimer's disease imaging agents for clinical studies. Frontiers in bioscience : a journal and virtual library. vol 13. 2007-12-11. PMID:17981587. |
alzheimer's disease (ad) is a neurodegenerative disease characterized by a progressive loss of neurotransmitters, as well as acetylcholinesterase and nicotinic acetylcholine receptors in the central nervous system that leads to learning and memory deficits, among other problems. |
2007-12-11 |
2023-08-12 |
human |
| Young Ee Kwon, Jung Youl Park, Kyung Tai No, Jae Hong Shin, Sung Kwang Lee, Jae Soon Eun, Jae Heon Yang, Tae Yong Shin, Dae Keun Kim, Byung Sook Chae, Jae-Yoon Leem, Kuk Hwan Ki. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorganic & medicinal chemistry. vol 15. issue 20. 2007-12-06. PMID:17681794. |
synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and abeta1-42 aggregation for alzheimer's disease therapeutics. |
2007-12-06 |
2023-08-12 |
Not clear |